Fundz

Beam Therapeutics Inc. reported raising $45 Million in an initial SEC Form D filing

PUBLIC · BEAMAug 09, 2018

Amount Raised

$45 Million

$45 Million sold, per SEC Form D (first sale Aug 9, 2018)

Round Type

Venture

CambridgeBiotechnologyHealthcareHealth CareTherapeutics

Quick answer

Beam Therapeutics Inc. raised $45 Million in a funding round, dated August 9, 2018. Beam Therapeutics Inc. is based in Cambridge, Massachusetts, United States.

How much did Beam Therapeutics Inc. raise?
Beam Therapeutics Inc. raised $45 Million in a funding round on August 9, 2018.
What does Beam Therapeutics Inc. do?
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines.
Where is Beam Therapeutics Inc. based and how big is it?
Beam Therapeutics Inc. is based in Cambridge, Massachusetts, United States.

Source: Fundz verified event record.

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as Beam Therapeutics Inc. that raised within 45 days of this round, from Fundz verified event records.

  • CytoDyn raised $13M on September 10, 2018.
  • Olema Pharmaceuticals, Inc. raised $6.1M on August 27, 2018.
  • vTv Therapeutics Inc. raised an undisclosed amount on August 10, 2018.
  • BehaVR raised $500K (Seed) on July 25, 2018.
  • VistaGen raised $4.8M on September 21, 2018.
  • Valitor raised $1.7M (Seed) on September 21, 2018.

Who to call at Beam Therapeutics Inc., and when

A new round usually means Beam Therapeutics Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Beam Therapeutics Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Beam Therapeutics Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Beam Therapeutics Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Beam Therapeutics Inc.

Location

325 VASSAR STREET, SUITE 2A

Cambridge, Massachusetts, United States

About

Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Beam Therapeutics Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Beam Therapeutics Inc.'s next move

See what Strategic adds

Beam Therapeutics Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.